Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LSB LakeShore Biopharma	$0.83 -0.8%	$0.95	$0.59 ▼ $8.60	$17.22M	0.56	75,822 shs	5,242 shs
PULM Pulmatrix	$4.89 +9.4%	$6.07	$1.78 ▼ $10.40	N/A	1.45	11,293 shs	14,341 shs
XBIO Xenetic Biosciences	$2.89 +2.3%	$3.33	$2.20 ▼ $5.27	$4.67M	2.31	36,288 shs	20,458 shs
XFOR X4 Pharmaceuticals	$3.92 +23.3%	$2.05	$1.35 ▼ $26.83	$44.72M	0.6	10.57 million shs	3.26 million shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LSB LakeShore Biopharma	0.00%	+6.28%	-36.72%	-22.60%	-81.65%
PULM Pulmatrix	0.00%	+3.82%	-12.83%	-28.19%	+135.10%
XBIO Xenetic Biosciences	0.00%	+0.91%	-20.71%	-6.30%	-29.26%
XFOR X4 Pharmaceuticals	0.00%	+37.54%	+114.21%	+26.45%	-83.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LSB LakeShore Biopharma	0.6231 of 5 stars	0.0	5.0	0.0	0.0	0.8	0.6
PULM Pulmatrix	0.4119 of 5 stars	0.0	5.0	0.0	1.1	0.0	0.0
XBIO Xenetic Biosciences	0.9811 of 5 stars	0.0	3.0	0.0	3.4	0.8	0.6
XFOR X4 Pharmaceuticals	4.2351 of 5 stars	3.5	2.0	4.6	3.1	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LSB LakeShore Biopharma	0.00	N/A	N/A	N/A
PULM Pulmatrix	0.00	N/A	N/A	N/A
XBIO Xenetic Biosciences	2.00	Hold	N/A	N/A
XFOR X4 Pharmaceuticals	3.00	Buy	$71.17	1,715.48% Upside

Current Analyst Ratings Breakdown

Latest XBIO, LSB, XFOR, and PULM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/13/2025	XFOR X4 Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$7.00 ➝ $3.50

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LSB LakeShore Biopharma	$85.67M	0.20	N/A	N/A	$3.35 per share	0.25
PULM Pulmatrix	$7.81M	N/A	N/A	N/A	$2.45 per share	N/A
XBIO Xenetic Biosciences	$2.50M	1.78	N/A	N/A	$2.88 per share	1.00
XFOR X4 Pharmaceuticals	$2.56M	17.47	N/A	N/A	$0.35 per share	11.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LSB LakeShore Biopharma	-$13.93M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
PULM Pulmatrix	-$6.94M	-$2.17	N/A	∞	N/A	-122.46%	-97.25%	-88.96%	11/6/2025 (Estimated)
XBIO Xenetic Biosciences	-$3.96M	-$2.00	N/A	N/A	N/A	-126.08%	-54.56%	-47.28%	11/11/2025 (Estimated)
XFOR X4 Pharmaceuticals	-$37.45M	-$14.84	N/A	N/A	N/A	-311.15%	-375.31%	-72.87%	11/12/2025 (Estimated)

Latest XBIO, LSB, XFOR, and PULM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	XBIO Xenetic Biosciences	-$0.64	-$0.45	+$0.19	-$0.45	$0.48 million	$0.59 million
8/8/2025	Q2 2025	XFOR X4 Pharmaceuticals	-$4.53	-$3.47	+$1.06	-$3.47	$1.62 million	$1.97 million
8/6/2025	Q2 2025	PULM Pulmatrix	N/A	-$0.42	N/A	-$0.42	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LSB LakeShore Biopharma	N/A	N/A	N/A	N/A	N/A
PULM Pulmatrix	N/A	N/A	N/A	N/A	N/A
XBIO Xenetic Biosciences	N/A	N/A	N/A	N/A	N/A
XFOR X4 Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LSB LakeShore Biopharma	0.05	1.02	0.75
PULM Pulmatrix	N/A	11.21	11.21
XBIO Xenetic Biosciences	N/A	5.93	5.93
XFOR X4 Pharmaceuticals	19.10	3.19	3.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LSB LakeShore Biopharma	52.64%
PULM Pulmatrix	11.84%
XBIO Xenetic Biosciences	15.12%
XFOR X4 Pharmaceuticals	72.03%

Insider Ownership

Company	Insider Ownership
LSB LakeShore Biopharma	N/A
PULM Pulmatrix	0.62%
XBIO Xenetic Biosciences	14.70%
XFOR X4 Pharmaceuticals	2.37%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LSB LakeShore Biopharma	773	20.77 million	N/A	N/A
PULM Pulmatrix	20	N/A	N/A	Not Optionable
XBIO Xenetic Biosciences	4	1.54 million	1.32 million	Not Optionable
XFOR X4 Pharmaceuticals	80	11.41 million	11.14 million	Optionable

XBIO, LSB, XFOR, and PULM Headlines

Recent News About These Companies

Brookline Capital Management Comments on XFOR Q3 Earnings

August 21 at 2:15 AM | americanbankingnews.com

Q3 EPS Forecast for X4 Pharmaceuticals Lifted by Analyst

August 17, 2025 | americanbankingnews.com

X4 Pharmaceuticals Grants Inducement Equity Awards to New Executive Officers

August 15, 2025 | quiverquant.comQ

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 15, 2025 | globenewswire.com

X4 Pharmaceuticals Closes $85M Private Placement Deal

August 14, 2025 | theglobeandmail.com

X4 Pharmaceuticals price target lowered to $3.50 from $7 at H.C. Wainwright

August 13, 2025 | msn.com

X4 Pharmaceuticals Stock Rises On Closing Of Upsized Offering, But Brokerage Lowers Price Target

August 13, 2025 | msn.com

X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement

August 13, 2025 | globenewswire.com

X4 Pharmaceuticals announces $60M financing, management changes

August 12, 2025 | msn.com

X4 Pharmaceuticals Announces $60M Equity Financing

August 12, 2025 | msn.com

X4 Pharmaceuticals secures $60M PIPE financing

August 12, 2025 | msn.com

X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership

August 12, 2025 | globenewswire.com

X4 Pharmaceuticals, Inc. (XFOR) - Yahoo Finance

July 3, 2025 | finance.yahoo.com

X4 Pharmaceuticals Inc News (XFOR) - Investing.com

July 2, 2025 | investing.com

XFOR X4 Pharmaceuticals, Inc. - Seeking Alpha

June 26, 2025 | seekingalpha.com

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)

June 16, 2025 | globenewswire.com

X4 Pharmaceuticals Gets Fast Track Regulatory Designation for Neutropenia Drug

June 10, 2025 | marketwatch.com

X4 Pharmaceuticals gains on fast-track designation for mavorixafor for treatment of chronic neutropenia

June 10, 2025 | msn.com

X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA

June 10, 2025 | globenewswire.com

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 2, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIO, LSB, XFOR, and PULM Company Descriptions

LakeShore Biopharma NASDAQ:LSB

$0.83 -0.01 (-0.84%)

Closing price 08/22/2025 03:58 PM Eastern

Extended Trading

$0.82 -0.01 (-0.60%)

As of 08/22/2025 04:17 PM Eastern

LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.

Pulmatrix NASDAQ:PULM

$4.77 +0.30 (+6.62%)

As of 08/22/2025 04:00 PM Eastern

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.

Xenetic Biosciences NASDAQ:XBIO

$2.89 +0.07 (+2.34%)

Closing price 08/22/2025 03:19 PM Eastern

Extended Trading

$2.91 +0.02 (+0.83%)

As of 08/22/2025 06:55 PM Eastern

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

X4 Pharmaceuticals NASDAQ:XFOR

$3.92 +0.74 (+23.27%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$3.74 -0.19 (-4.72%)

As of 08/22/2025 07:59 PM Eastern

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time